Session Title: Refractive
Session Date/Time: Sunday 17/02/2013 | 08:30-11:00
Paper Time: 09:58
Venue: Hall 3
First Author: : B.Kałużny POLAND
Co Author(s): : I. Cieślińska
Purpose:
TransPRK is a new variant of transepithelial PRK in which both epithelium and stroma are removed in a single step, with respect to a population model of epithelial thickness. The aim of this study is to present 3-month results of myopia and compound myopic astigmatism correction with TransPRK with Schwind Amaris 750 S.
Setting:
Oftalmika Eye Hospital, Department of Ophthalmology of Collegium Medicum NCU, Bydgoszcz, Poland
Methods:
A total number of 114 consecutive eyes (61 patients) with myopia or myopic compound astigmatism were enrolled. Mean preoperative spherical equivalent was -4.03 D ± 2.01 D (-0.50 to -9.25 D) and mean preoperative refractive cylinder was -1.32 D ± 1.32 D (0.00 to -5.50). TransPRK procedures were performed with the Amaris 750S (Schwind, Germany). In all cases 0.02 % MMC was applied for 2 min. Refractive results, predictability, safety, and efficacy were evaluated 3 months after the surgery.
Results:
Mean postoperative spherical equivalent was -0.10 D ± 0.23 D (+0.50 to -0.75), mean cylinder -0.08 D ± 0.19 D (0.00 to -0.75). Ninety-eight percent of eyes were within ±0.50 D of attempted spherical correction and 96% were within ±0.50 D of cylindrical correction. Uncorrected visual acuity after the surgery was 20/20 or better in 97% of eyes. Twenty-nine percent of eyes lost one line of CDVA, 24 % gained 1 line. In postoperative course minimal haze in 9 % of eyes was noted and in 3 % of eyes increased IOP was observed.
Conclusions:
TransPRK with the Amaris 750S is a predictable, effective and safe procedure for myopia and compound myopic astigmatism correction.
Financial Disclosure:
... travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented
